BACKGROUND: Pharmacokinetic study has shown that co-administration of cyclosporin A (CsA), which acts as a P-glycoprotein (P-gp) and CYP-3A blocker, resulted in an 8-fold increase in the systemic exposure of oral paclitaxel. Two doses of oral paclitaxel on 1 day in combination with CsA resulted in higher systemic exposure than single dose administration. PATIENTS AND METHODS: In this phase II study, chemonaïve patients with advanced gastric cancer received oral paclitaxel weekly in two doses of 90 mg/m(2) on the same day; CsA (10 mg/kg) was given 30 min before each dose of oral paclitaxel. RESULTS: In 25 patients, the main toxicities were: nausea CTC grade 2/3, 10 patients (40%); vomiting grade 2/3, 4 patients (20%); diarrhea grade 2/3, 6 patients (24%); neutropenia grade 3/4, 5 patients (20%). In the 24 evaluable patients, eight partial responses were observed, resulting in an overall response rate (ORR) of 33% [95% confidence interval (CI) 18% to 52%]. Eleven patients had stable disease (46%) and 5 patients showed progressive disease (21%). The ORR in the total population was 32% (95% CI 17% to 50%). The median time to progression was 16 weeks (95% CI 9-22). Pharmacokinetic analyses revealed that the mean area under the plasma concentration-time curve (AUC) of orally administered paclitaxel (+/- standard deviation) was 3757.6 +/- 939.4 ng.h/ml in week 1 and 3928.4 +/- 1281 ng.h/ml in week 2. The intrapatient variability in the AUC was 12%. CONCLUSIONS: Oral paclitaxel in combination with CsA is both active and safe in chemonaïve patients with advanced gastric cancer. Toxicities were mainly gastrointestinal.
BACKGROUND: Pharmacokinetic study has shown that co-administration of cyclosporin A (CsA), which acts as a P-glycoprotein (P-gp) and CYP-3A blocker, resulted in an 8-fold increase in the systemic exposure of oral paclitaxel. Two doses of oral paclitaxel on 1 day in combination with CsA resulted in higher systemic exposure than single dose administration. PATIENTS AND METHODS: In this phase II study, chemonaïve patients with advanced gastric cancer received oral paclitaxel weekly in two doses of 90 mg/m(2) on the same day; CsA (10 mg/kg) was given 30 min before each dose of oral paclitaxel. RESULTS: In 25 patients, the main toxicities were: nausea CTC grade 2/3, 10 patients (40%); vomiting grade 2/3, 4 patients (20%); diarrhea grade 2/3, 6 patients (24%); neutropenia grade 3/4, 5 patients (20%). In the 24 evaluable patients, eight partial responses were observed, resulting in an overall response rate (ORR) of 33% [95% confidence interval (CI) 18% to 52%]. Eleven patients had stable disease (46%) and 5 patients showed progressive disease (21%). The ORR in the total population was 32% (95% CI 17% to 50%). The median time to progression was 16 weeks (95% CI 9-22). Pharmacokinetic analyses revealed that the mean area under the plasma concentration-time curve (AUC) of orally administered paclitaxel (+/- standard deviation) was 3757.6 +/- 939.4 ng.h/ml in week 1 and 3928.4 +/- 1281 ng.h/ml in week 2. The intrapatient variability in the AUC was 12%. CONCLUSIONS: Oral paclitaxel in combination with CsA is both active and safe in chemonaïve patients with advanced gastric cancer. Toxicities were mainly gastrointestinal.
Authors: Heleen A Bardelmeijer; Mariët Ouwehand; Jos H Beijnen; Jan H M Schellens; Olaf van Tellingen Journal: Invest New Drugs Date: 2004-08 Impact factor: 3.850
Authors: Roos L Oostendorp; T Buckle; G Lambert; J S Garrigue; J H Beijnen; J H M Schellens; O van Tellingen Journal: Invest New Drugs Date: 2010-04-13 Impact factor: 3.850
Authors: Wen Wee Ma; Jenny J Li; Nilofer S Azad; Elaine T Lam; Jennifer R Diamond; Grace K Dy; Mateusz Opyrchal; Jay Zhi; Douglas Kramer; Wing-Kai Chan; David Cutler; Rudolf Kwan; Alex A Adjei; Antonio Jimeno Journal: Cancer Chemother Pharmacol Date: 2022-06-22 Impact factor: 3.288
Authors: Milly E de Jonge; Alwin Dr Huitema; Jan Hm Schellens; Sjoerd Rodenhuis; Jos H Beijnen Journal: Br J Clin Pharmacol Date: 2005-03 Impact factor: 4.335
Authors: Min Kyoung Kim; Kyung Hee Lee; Myung Soo Hyun; Young Rok Do; Hong Suk Song; Won Sik Lee; Keon Uk Park; Jin Ho Baek; Jong Gwang Kim Journal: Cancer Res Treat Date: 2005-12-31 Impact factor: 4.679
Authors: H H Helgason; C M F Kruijtzer; A D R Huitema; S G Marcus; W W ten Bokkel Huinink; M E Schot; J H Schornagel; J H Beijnen; J H M Schellens Journal: Br J Cancer Date: 2006-09-12 Impact factor: 7.640